VB
Vetmab Biosciences, Inc.
StreetZero Signal 78
About Vetmab Biosciences, Inc.
Vetmab Biosciences, Inc. is a veterinary biopharmaceutical company focused on developing monoclonal antibodies (mAbs) to treat debilitating diseases in dogs and cats. The company aims to bring revolutionary treatments from human medicine to the veterinary sector. It was founded in 2022 and is based in San Diego, California.
LATEST FUNDINGPrivate Placement
$11.4M
Announced 2026-09-29
IN THE NEWS
- 🔗 Vetmab Biosciences - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 VETmAb Biosciences, Inc. - Developing life-changing therapeutics for pets
- 🔗 Vetmab Biosciences - Products, Competitors, Financials, Employees, Headquarters Locations
- 🔗 Akston 2026 Company Profile: Valuation, Funding & Investors | PitchBook
- 🔗 One Biosciences (Biotechnology) 2026 Company Profile: Valuation, Funding & Investors | PitchBook
EMPLOYEES2-10
FOUNDED2022
HQSan Diego, CA, United States
Industry
Biotechnology
Tags
BiotechnologyVeterinary MedicineMonoclonal Antibodies
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Vetmab Biosciences develops monoclonal antibody therapies for dogs and cats.
- Founded in 2022 and headquartered in San Diego, California.
- Raised $11,439,990 in private placement funding.
- Focuses on treating debilitating diseases in pets using biotechnology.
Ask StreetZero about Vetmab Biosciences, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account